While GSK461364 exhibits established antitumor activity across multiple malignancies (e.g., lung carcinoma, breast cancer, hepatocellular carcinoma, osteosarcoma, and glioblastoma)[30, 31, 32, 33, 34, 35] and has completed phase I evaluation,[36] our study reveals its novel anti‐inflammatory properties via NLRP3 suppression. Here, NLRP3 is linked to lung carcinoma.